Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression
May 23, 2019Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression
Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …
Japan’s health ministry warns of serious side effects of Lilly’s Verzenio
May 23, 2019Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma
Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …
KCL study could lead to improved vaccinations against STIs
May 23, 2019Research and Development HIV, HSV, STIs, herpes, immune system, std
New findings from researchers at King’s College London could lead to improved vaccinations against sexually transmitted infections (STIs). Researchers at …
Akcea’s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR
May 23, 2019Sales and Marketing Akcea Therapeutics, NHS, NICE, Tegsedi, UK, pharma
Akcea Therapeutics’ Tegsedi (inotersen) has received recommendation from NICE, the company has revealed, meaning the therapy will now be made …
Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype
May 22, 2019Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma
Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …
Amgen agrees to buy Nuevolution for $167 million
May 22, 2019Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …
Takeda scores Japanese Entyvio approval in Crohn’s disease
May 22, 2019Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma
Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
MSD buys Peloton Therapeutics in deal worth $2.1 billion
May 22, 2019Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma
MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …
Children wait six and half years longer than adults for new cancer drugs, study says
May 22, 2019Research and Development Cancer, FDA, children, oncology, paediatrics, pharma
Children wait six and half years longer than adults to access new cancer drugs, according to a study from Dana-Farber/Boston …
New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression
May 21, 2019Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma
New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
GP appointments should be at least 15 minutes long by 2030, report argues
May 21, 2019Manufacturing and Production, Medical Communications GP, NHS, UK, britain, pharma
GP consultations should be five minutes longer, with 10 minute doctors’ appointments being a ‘thing of the past,’ according to …
Xenon halts effects of head injuries in mice
May 21, 2019Manufacturing and Production, Research and Development TBI, brain injury, head injury, pharma, xenon
Researchers at Imperial College London (ICL) and Johannes Gutenberg University Mainz have shown that xenon prevents early death and long-term …
Keytruda fails to improve overall survival in advanced triple-negative breast cancer
May 21, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer
MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …
AI better than radiologists at diagnosing lung cancer
May 21, 2019Manufacturing and Production AI, artificial intelligence, cancer screening, lung cancer, pharma ML
An artificial intelligence (AI) is better than specialist doctors at diagnosing lung cancer, according to a study from researchers at …
The global rise in antibiotic resistance threatens infection prevention and cure
May 20, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma
Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic …
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke
May 20, 2019Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure
Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show
May 20, 2019Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis
Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
Sandoz is first multinational to secure generic approval under new Chinese guidelines
May 20, 2019Sales and Marketing China, Novartis, Sandoz, generics, pharma, rosuvastatin
Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in …
NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma
May 20, 2019Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma
Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
